Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Mankind Pharma IPO is a book built issue of Rs 4,326.36 crores. The issue is entirely an offer for sale of 4.01 crore shares.
Mankind Pharma IPO bidding started from April 25, 2023 and ended on April 27, 2023. The allotment for Mankind Pharma IPO was finalized on Wednesday, May 3, 2023. The shares got listed on BSE, NSE on May 9, 2023.
Mankind Pharma IPO price band is set at ₹1026 to ₹1080 per share. The minimum lot size for an application is 13 Shares. The minimum amount of investment required by retail investors is ₹14,040. The minimum lot size investment for sNII is 15 lots (195 shares), amounting to ₹210,600, and for bNII, it is 72 lots (936 shares), amounting to ₹1,010,880.
Kotak Mahindra Capital Company Limited, Axis Capital Limited, Iifl Securities Ltd, Jefferies India Private Limited and J.P. Morgan India Private Limited are the book running lead managers of the Mankind Pharma IPO, while Kfin Technologies Limited is the registrar for the issue.
Refer to Mankind Pharma IPO RHP for detailed information.
| IPO Date | April 25, 2023 to April 27, 2023 |
| Listing Date | May 9, 2023 |
| Face Value | ₹1 per share |
| Price Band | ₹1026 to ₹1080 per share |
| Lot Size | 13 Shares |
| Total Issue Size | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Offer for Sale | 40,058,844 shares of ₹1 (aggregating up to ₹4,326.36 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Mankind Pharma IPO offers 40,058,844 shares. 8,011,769 (20.00%) to QIB, 6,008,827 (15.00%) to NII, 14,020,596 (35.00%) to RII 12,017,652 (30.00%) to Anchor investors. 1,078,507 RIIs will receive minimum 13 shares and 10,271 (sNII) and 20,543 (bNII) will receive minimum 195 shares. (in case of oversubscription)
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 12,017,652 (30.00%) | NA |
| QIB Shares Offered | 8,011,769 (20.00%) | NA |
| NII (HNI) Shares Offered | 6,008,827 (15.00%) | |
| bNII > ₹10L | 4,005,885 (10.00%) | 20,543 |
| sNII < ₹10L | 2,002,942 (5.00%) | 10,271 |
| Retail Shares Offered | 14,020,596 (35.00%) | 1,078,507 |
| Total Shares Offered | 40,058,844 (100%) |
Mankind Pharma IPO raises Rs 1,297.91 crore from anchor investors. Mankind Pharma IPO Anchor bid date is April 24, 2023. Mankind Pharma IPO Anchor Investors list
| Bid Date | April 24, 2023 |
| Shares Offered | 12,017,652 |
| Anchor Portion Size (In Cr.) | 1,297.91 |
| Anchor lock-in period end date for 50% shares (30 Days) | June 2, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | August 1, 2023 |
Mankind Pharma IPO opens on April 25, 2023, and closes on April 27, 2023.
| IPO Open Date | Tuesday, April 25, 2023 |
| IPO Close Date | Thursday, April 27, 2023 |
| Basis of Allotment | Wednesday, May 3, 2023 |
| Initiation of Refunds | Thursday, May 4, 2023 |
| Credit of Shares to Demat | Friday, May 5, 2023 |
| Listing Date | Tuesday, May 9, 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on April 27, 2023 |
Investors can bid for a minimum of 13 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹196,560 |
| S-HNI (Min) | 15 | 195 | ₹210,600 |
| S-HNI (Max) | 71 | 923 | ₹996,840 |
| B-HNI (Min) | 72 | 936 | ₹1,010,880 |
| Lot Size Calculator | |||
Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust are the company promoters.
| Share Holding Pre Issue | 79.00% |
| Share Holding Post Issue | 76.50% |
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing.
Mankind has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. They operate 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022.
As of December 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 5,073.29 | 5,975.65 | 1,056.15 | 3,485.31 | 3,436.34 | 126.92 |
| 31-Mar-21 | 6,372.63 | 6,385.38 | 1,293.03 | 4,722.00 | 4,674.39 | 234.53 |
| 31-Dec-21 | 8,043.88 | 6,218.29 | 1,260.24 | 5,965.46 | 5,916.86 | 268.70 |
| 31-Mar-22 | 9,147.74 | 7,977.58 | 1,452.96 | 6,155.23 | 6,106.06 | 868.03 |
| 31-Dec-22 | 9,273.75 | 6,777.82 | 1,015.98 | 7,145.89 | 7,094.12 | 167.93 |
| Amount in ₹ Crore | ||||||
The market capitalization of Mankind Pharma IPO is Rs 43263.6 Cr.
| KPI | Values |
|---|---|
| ROE | 27.60% |
| ROCE | 26.10% |
| RoNW | 27.70% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 33.2 | |
| P/E (x) | 32.5 |
The company will not receive any proceeds from the offer and all the offer proceeds will be received by the selling shareholders, in proportion to the offered shares sold by the respective selling shareholders as part of the offer.
[Dilip Davda] A major domestic player in healthcare products is going public with a pure vanilla OFS issue. It is diluting just 10% now. It has shown good financial performance from FY20 to FY22. The setback for 9m of FY23 is due to one-time provisioning for its recent takeovers. Based on recent performance, the issue appears fully priced. It’s a long race horse, hence investors may consider parking funds with a long-term perspective. Read detail review...
The Mankind Pharma IPO is subscribed 15.32 times on April 27, 2023 7:02:00 PM. The public issue subscribed 0.92 times in the retail category, 49.16 times in the QIB category, and 3.80 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 49.16 |
| NII | 3.80 |
| bNII (bids above ₹10L) | 4.99 |
| sNII (bids below ₹10L) | 1.41 |
| Retail | 0.92 |
| Total | 15.32 |
Total Application : 462,789 (0.43 times)
| Listing Date | May 9, 2023 |
| BSE Script Code | 543904 |
| NSE Symbol | MANKIND |
| ISIN | INE634S01028 |
| Final Issue Price | ₹1080 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹1,080.00 |
| ₹1,300.00 |
| ₹1,300.00 |
| ₹1,430.00 |
| ₹1,424.05 |
| NSE |
|---|
| ₹1,080.00 |
| ₹1,300.00 |
| ₹1,300.00 |
| ₹1,430.00 |
| ₹1,080.00 |
Mankind Pharma Limited
208, Okhla Industrial Estate
Phase-III,
New Delhi 110020
Phone: +91 11 4684 6700
Email: investors@mankindpharma.com
Website: https://www.mankindpharma.com/
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: mankind.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Mankind Pharma IPO is a main-board IPO of 40,058,844 equity shares of the face value of ₹1 aggregating up to ₹4,326.36 Crores. The issue is priced at ₹1026 to ₹1080 per share. The minimum order quantity is 13 Shares.
The IPO opens on April 25, 2023, and closes on April 27, 2023.
Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Mankind Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Mankind Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Mankind Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Mankind Pharma IPO opens on April 25, 2023 and closes on April 27, 2023.
Mankind Pharma IPO lot size is 13 Shares, and the minimum amount required is ₹14,040.
You can apply in Mankind Pharma IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Mankind Pharma IPO will be done on Wednesday, May 3, 2023, and the allotted shares will be credited to your demat account by Friday, May 5, 2023. Check the Mankind Pharma IPO allotment status.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
IPO Mentor (1100+ Posts, 400+ Likes)
IPO Guru (3200+ Posts, 5300+ Likes)
Top Contributor (400+ Posts, 200+ Likes)
IPO KING MAKER| Link | Bookmark |May 30, 2023 5:21:08 PM